Tirzepatide
GIP/GLP-1 Dual Agonist
HGH 191AA
Somatotropin
| Property | Tirzepatide | HGH 191AA |
|---|---|---|
| Category | GIP/GLP-1 Dual Agonist | Somatotropin |
| Formula | C₂₂₅H₃₄₈N₄₈O₆₈ | 191 amino acids |
| Molecular Weight | 4,813.45 g/mol | 22,124 Da |
| Published Studies | 47+ | 500+ |
| Clinical Status | FDA-Approved (2022) | FDA-Approved (Rx Only) |
| Overview | The first dual-incretin agonist, simultaneously targeting GIP and GLP-1 receptors. FDA-approved as Mounjaro® and Zepbound®. | A 191-amino-acid recombinant growth hormone studied for GH-R/JAK2-STAT5 signaling and IGF-1 axis modulation. |
Tirzepatide — Key Details
What Is Tirzepatide?
Tirzepatide is a first-in-class dual GIP/GLP-1 receptor agonist — meaning it activates two incretin receptors simultaneously. Developed by Eli Lilly, it received FDA approval in 2022 as Mounjaro® for type 2 diabetes and in 2023 as Zepbound® for weight management.
Unlike single-target GLP-1 drugs (semaglutide), tirzepatide's dual mechanism is believed to produce synergistic metabolic effects that neither receptor activation alone can achieve.
How Does It Work?
Tirzepatide binds to both GIP receptors and GLP-1 receptors on cell surfaces, triggering intracellular cAMP signaling cascades. GLP-1 activation stimulates insulin secretion and suppresses glucagon. GIP activation enhances insulin sensitivity and influences energy metabolism and fat storage.
Key Clinical Data
- SURPASS-2 trial: Tirzepatide demonstrated superior A1C reduction vs. semaglutide in head-to-head comparison (Frías et al., 2021, NEJM)
- SURMOUNT-1 trial: Participants receiving 15mg tirzepatide achieved mean weight reduction of 22.5% over 72 weeks (Jastreboff et al., 2022, NEJM)
- Phase 3 trials are ongoing for MASH/NASH, heart failure with preserved ejection fraction, and obstructive sleep apnea
Sources
- According to Frías, J.P. et al. (2021). "Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes." NEJM, 385(6), 503-515. [PubMed]
- According to Jastreboff, A.M. et al. (2022). "Tirzepatide Once Weekly for the Treatment of Obesity." NEJM, 387(3), 205-216. [PubMed]
- According to Rosenstock, J. et al. (2021). "Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide." The Lancet, 398(10295), 143-155. [PubMed]
HGH 191AA — Key Details
What Is HGH 191AA?
HGH 191AA refers to recombinant human growth hormone — a 191-amino-acid protein identical to the somatotropin produced by the anterior pituitary gland. FDA-approved forms (Humatrope®, Norditropin®, Genotropin®) are prescription drugs used to treat growth hormone deficiency.
How It Works
Growth hormone binds to GH receptors on cell surfaces, activating the JAK2-STAT5 signaling pathway. This triggers the liver to produce IGF-1 (Insulin-like Growth Factor 1), which mediates most of GH's downstream effects on tissue growth, protein synthesis, and lipid metabolism.
Regulatory Status
FDA-approved as a prescription drug for growth hormone deficiency, Turner syndrome, chronic kidney disease, and Prader-Willi syndrome. Off-label use or distribution outside of legitimate medical prescriptions is a federal crime under the 1990 Anabolic Steroids Control Act. Research-grade somatotropin is used as a reference standard in binding assays.
Sources
- According to Ranke, M.B. & Wit, J.M. (2018). "Growth hormone — past, present and future." Nature Reviews Endocrinology, 14, 285-300. [PubMed]
- According to Møller, N. & Jørgensen, J.O. (2009). "Effects of growth hormone on glucose, lipid, and protein metabolism." Endocrine Reviews, 30(2), 152-177. [PubMed]